Development And Validation of a Simple, Precise, Accurate, And Reproducible RP-HPLC Method for Simultaneous Estimation of Metformin Hydrochloride and Glimepiride in Combined Dosage Form

Diabetes mellitus is one of the most prevalent chronic metabolic disorders worldwide, and type 2 diabetes mellitus (T2DM) accounts for the overwhelming majority of cases. T2DM arises from a combination of peripheral insulin resistance in skeletal muscle, liver, and adipose tissue, excessive hepatic glucose output, and a progressive decline in pancreatic β-cell function and mass [1]. Because no single class of antihyperglycaemic agent corrects all of these defects simultaneously, current treatment approaches increasingly favour combination therapy, recommending the addition of a second or third agent with a complementary mechanism once glycaemic targets are not met with a single drug [1].

Metformin Hydrochloride remains the universally recommended first-line oral agent for T2DM owing to its established efficacy, favourable cardiovascular and weight profile, and low cost. When glycaemic control is inadequate on metformin alone, a sulfonylurea such as Glimepiride is among the most frequently added agents, because it works through a distinct mechanism, namely direct stimulation of pancreatic insulin secretion, rather than improving insulin sensitivity. Clinical evidence indicates that combining metformin with a sulfonylurea produces a greater reduction in glycated haemoglobin (HbA1c) than either drug alone [2], and this two-drug combination is marketed worldwide as a fixed-dose combination (FDC) tablet whose bioequivalence to free combinations of the individual drugs has been confirmed in pharmacokinetic studies [2]. Fixed-dose combinations of this kind reduce the number of tablets a patient must take daily, a feature that has been associated with improved adherence and sustained glycaemic control in large, real-world patient populations [3,4].

The continuing clinical importance of the Metformin-Glimepiride combination, including its role as the background therapy onto which newer agents are now being added in triple fixed-dose combinations [1,4], places a direct and ongoing responsibility on pharmaceutical quality control laboratories to confirm that every batch of the combined dosage form contains the correct, uniform, and stable quantity of each active ingredient. Because the two drugs are co-formulated in the same tablet yet differ greatly in dose strength, aqueous solubility, and ionisation behaviour, conventional single-drug assay procedures are not directly transferable, and a dedicated, validated method capable of resolving and quantifying both actives within a single chromatographic run is required.

Reversed-phase high-performance liquid chromatography (RP-HPLC) has become the analytical method of choice for this purpose because of its high resolving power, sensitivity, reproducibility, and compatibility with the instrumentation already available in most pharmaceutical quality control laboratories. This review brings together the published literature on RP-HPLC methods developed for the simultaneous estimation of Metformin Hydrochloride and Glimepiride, examines the chromatographic strategies and method-development logic employed by different researchers, and summarises the validation parameters specified under the ICH Q2(R1) guideline, with the broader aim of providing analysts with a structured and consolidated reference point for future method development on this important drug combination.

2. DRUG PROFILE

2.1 METFORMIN HYDROCHLORIDE

Metformin Hydrochloride is chemically designated as N,N-dimethylimidodicarbonimidic diamide hydrochloride, commonly known as 1,1-dimethylbiguanide hydrochloride, with the molecular formula C₄H₁₁N₅ · HCl and a molecular weight of approximately 165.6 g/mol [5]. It occurs as a white, odourless, crystalline powder that is freely soluble in water, slightly soluble in alcohol, and practically insoluble in acetone and chloroform, with a reported melting point of 222-226 °C [5,6]. The molecule contains two imino and one amino donor centre and behaves as a strong base, exhibiting pKa values of approximately 2.8 and 11.5, so that it exists almost entirely in its protonated, cationic form across the physiological and most chromatographic pH ranges [5,6]. Owing to its high aqueous solubility combined with comparatively limited membrane permeability, metformin is classified under the Biopharmaceutics Classification System (BCS) as a Class III drug.

Pharmacologically, metformin is a biguanide antihyperglycaemic agent. Its principal mechanism of action involves suppression of hepatic gluconeogenesis, a modest reduction in intestinal glucose absorption, and improvement of peripheral glucose uptake and insulin sensitivity in skeletal muscle, largely mediated through activation of AMP-activated protein kinase (AMPK) signalling [5]. Because it does not stimulate pancreatic insulin secretion, metformin carries a low intrinsic risk of hypoglycaemia when used alone, and it is administered orally in doses typically ranging from 500 mg to 2000 mg per day.

2.2 GLIMEPIRIDE

Glimepiride is chemically described as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrrolin-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl) urea, with the molecular formula C₂₄H₃₄N₄O₅S and a molecular weight of about 490.6 g/mol [7]. It is obtained as a white to faintly yellowish crystalline powder that is practically insoluble in water, slightly soluble in methylene chloride, and very slightly soluble in methanol, with a melting point near 207 °C [7,8]. Glimepiride behaves as a weak acid with a pKa of approximately 6.2 and possesses comparatively high lipophilicity (log P ≈ 3.5-3.8), and it is classified as a BCS Class II drug because of its high intestinal permeability combined with poor aqueous solubility, particularly at acidic and neutral pH [7,8].

Glimepiride belongs to the sulfonylurea class of insulin secretagogues. It binds to the sulfonylurea receptor (SUR1) subunit of ATP-sensitive potassium (K_ATP) channels on pancreatic β-cells, causing channel closure, membrane depolarisation, calcium influx, and the exocytotic release of insulin, with additional modest extrapancreatic effects that enhance peripheral insulin sensitivity. Glimepiride is administered in much smaller doses than metformin, typically 1-8 mg per day, and its low aqueous solubility combined with high potency means it must be reliably detected at concentrations several-fold lower than metformin within the same chromatographic run – one of the principal analytical challenges that the methods reviewed in this article are designed to overcome.

2.3 COMPARATIVE PHYSICOCHEMICAL AND PHARMACOLOGICAL PROFILE

Table 1 summarises the key physicochemical and pharmacological characteristics of the two drugs side by side, illustrating the extent to which they differ in polarity, solubility, and dose strength – differences that directly shape the chromatographic strategy required for their simultaneous estimation.

2.4 RATIONALE FOR THE FIXED-DOSE COMBINATION

Clinical and pharmacokinetic evidence supports the rationale for combining Metformin Hydrochloride and Glimepiride within a single tablet. Bioequivalence studies of the 2 mg / 500 mg fixed-dose combination have demonstrated comparable pharmacokinetic performance between generic and reference formulations, supporting their therapeutic interchangeability [2]. Large, real-world studies involving thousands of patients on Metformin-Glimepiride combinations have reported sustained glycaemic control and acceptable safety profiles across a wide range of disease durations and comorbidities [3]. More recent triple-combination trials, in which Metformin and Glimepiride together form the background therapy onto which additional agents such as sodium-glucose co-transporter-2 (SGLT2) inhibitors are added, further illustrate the continuing and expanding clinical relevance of this two-drug combination as a therapeutic backbone in T2DM management [1,4]. This sustained, widespread, and evolving clinical use is the principal driver behind continued analytical method development, since every new strength, formulation, or combination product containing Metformin and Glimepiride requires a validated assay method for regulatory approval and routine quality control.

3. NEED FOR A SIMULTANEOUS RP-HPLC METHOD

Several factors make the simultaneous estimation of Metformin Hydrochloride and Glimepiride analytically demanding and explain the emphasis placed on RP-HPLC throughout the literature reviewed in this article:

• Disparate dose strengths: A typical fixed-dose tablet contains metformin in the 500-1000 mg range alongside glimepiride in the 1-4 mg range, a ratio that can exceed 250:1. The chromatographic and detection system must provide adequate sensitivity for the minor component without saturating the detector response for the major component.
• Divergent physicochemical behaviour: Metformin is highly polar, water-soluble, and exists predominantly as a cation, whereas glimepiride is lipophilic, poorly water-soluble, and behaves as a weak acid. A single mobile phase system must elute and resolve both compounds with acceptable peak shape and resolution.
• Overlapping UV absorption: Both drugs absorb in the low-UV region, so the detection wavelength must be chosen carefully, often close to a compromise or isosbestic wavelength, to allow simultaneous quantification with acceptable sensitivity for both analytes in one run.
• Regulatory and pharmacopoeial requirements: Assay, content uniformity, dissolution, and stability testing of combination products require methods that are formally validated according to ICH Q2(R1) guidelines and, where applicable, official pharmacopoeial monographs.
• Stability-indicating capability: Because combination tablets may be exposed to heat, humidity, and acidic, alkaline, or oxidative stress during storage, many reported methods are designed to resolve the parent drugs from their degradation products, adding a further dimension to method development.

RP-HPLC addresses each of these challenges effectively, offering high resolving power, the flexibility to tune selectivity through stationary phase chemistry, mobile phase pH and composition, and detector wavelength, together with excellent reproducibility suited to routine quality control use. These attributes collectively explain the dominance of RP-HPLC in the published literature on this drug combination.

4. ANALYTICAL TECHNIQUES REPORTED FOR METFORMIN HYDROCHLORIDE AND GLIMEPIRIDE: A LITERATURE OVERVIEW

A range of analytical techniques has been reported for the estimation of Metformin Hydrochloride and Glimepiride, either individually or in combination with other antidiabetic drugs. UV spectrophotometric methods, including simultaneous equation, absorbance ratio, and derivative spectroscopy approaches, have been used for rapid and economical estimation, but they generally lack the resolving power needed when more than one drug, or a degradation product, is present in the sample. High-performance thin-layer chromatography (HPTLC) methods allow simultaneous analysis of multiple samples at relatively low cost but typically offer lower precision and sensitivity than column-based liquid chromatography. Liquid chromatography-mass spectrometry (LC-MS/MS) methods provide the highest sensitivity and specificity and are mainly employed for bioanalytical and pharmacokinetic studies in biological matrices such as plasma, but their high instrumentation and running cost limit their routine use in pharmaceutical quality control settings.

RP-HPLC with UV or photodiode-array (PDA) detection occupies the middle ground between these techniques, combining good resolution, sensitivity, and robustness with instrumentation that is widely available in pharmaceutical quality control laboratories, which explains its predominance in the published literature concerning this drug pair. Table 2 summarises representative RP-HPLC methods reported for the simultaneous estimation of Metformin Hydrochloride and Glimepiride, either as a binary mixture or together with a third antidiabetic agent in triple-combination products, illustrating the diversity of stationary phases, mobile phase systems, and detection wavelengths that have been successfully validated for this drug combination.

Several patterns emerge from this body of literature. Most methods employ a C18 (octadecylsilane) reversed-phase column with 5 µm particle size and a column length between 100 and 250 mm, operated at or near ambient temperature. Mobile phases are predominantly isocratic mixtures of methanol or acetonitrile with an aqueous phosphate buffer, with the buffer pH adjusted usually between pH 2.5 and 5.5 using orthophosphoric acid to control the ionisation state of metformin and achieve adequate peak symmetry. Detection wavelengths cluster in the 225-260 nm range, reflecting the overlapping UV absorption of the two drugs. Flow rates around 1.0 mL/min and total run times under 15 minutes are typical, making these methods suitable for high-throughput routine analysis. Reported linearity ranges consistently mirror the large dose disparity between the two drugs, with metformin validated over a much higher concentration range than glimepiride in every binary method reviewed [9,10].

5. PRINCIPLE AND INSTRUMENTATION OF RP-HPLC

Reversed-phase HPLC separates analytes on the basis of differential partitioning between a non-polar stationary phase, typically octadecylsilane (C18) or octylsilane (C8) bonded silica, and a comparatively polar mobile phase composed of water or aqueous buffer mixed with a water-miscible organic modifier such as methanol or acetonitrile. Polar analytes elute earlier and non-polar analytes are retained longer, which is consistent with the elution order observed across the methods reviewed, where the highly polar metformin consistently elutes well before the comparatively lipophilic glimepiride [9,10,15].

A typical RP-HPLC system used for this drug combination comprises a high-pressure isocratic pump, a manual or automated injector, a thermostated C18 or C8 analytical column, a UV or PDA detector operated in the 225-260 nm range, and data-acquisition software for peak integration and quantification. Buffer pH control is particularly important for metformin, since it is a strong base with pKa values of 2.8 and 11.5 and will exist in different ionisation states depending on mobile phase pH, which directly affects its retention behaviour and peak shape on a reversed-phase column.

6. METHOD DEVELOPMENT CONSIDERATIONS

6.1 SELECTION OF DETECTION WAVELENGTH

Because metformin and glimepiride do not share an identical UV absorption maximum, method developers typically scan both drugs individually and as a mixture using a PDA detector to identify either an isosbestic point or a single compromise wavelength that provides adequate sensitivity for both analytes without requiring wavelength switching during the run. Reported detection wavelengths for this pair and its related multi-drug combinations span 226-260 nm, with values around 230-240 nm being the most frequently validated [9,10,12,15,16].

6.2 SELECTION OF COLUMN AND STATIONARY PHASE

A C18 column of 4.6 mm internal diameter, 100-250 mm length, and 5 µm particle size is the most common choice across the reviewed methods, providing a balance of resolution, analysis time, and back-pressure suitable for routine isocratic separations. C8 stationary phases have also been used successfully, generally with comparable mobile phase strategies [15].

6.3 MOBILE PHASE OPTIMISATION

Mobile phase optimisation is the most critical step in developing a method for this drug pair. Because metformin is highly polar and ionisable while glimepiride is comparatively non-polar, the aqueous buffer component, organic modifier ratio, and pH must be optimised together. Phosphate buffers adjusted to a mildly acidic pH (approximately 2.5-5.5) are widely used to protonate the basic groups on metformin and stabilise its retention, while the proportion of methanol or acetonitrile is adjusted to achieve sufficient retention and resolution of glimepiride without an excessive run time. Some methods incorporate an ion-pairing reagent, such as hexane-1-sulphonic acid, to further improve the peak shape and retention of metformin on the reversed-phase column [10].

6.4 FLOW RATE AND COLUMN TEMPERATURE

A flow rate of approximately 1.0 mL/min at ambient or slightly above ambient column temperature is typical across the reviewed methods, providing adequate resolution within a practical analysis time of roughly 6-15 minutes.

6.5 DESIGN OF EXPERIMENTS AND QUALITY BY DESIGN APPROACHES

More recent work has applied Quality by Design (QbD) principles, using risk-assessment tools to identify critical method parameters, followed by formal experimental designs such as fractional factorial and Box-Behnken response-surface designs, to systematically map the relationship between chromatographic variables and method performance and to define a validated operating "design space" within which the method remains robust [16]. This approach represents a shift away from the traditional one-factor-at-a-time optimisation seen in earlier publications towards a more statistically rigorous and regulation-aligned method-development strategy.

7. METHOD VALIDATION AS PER ICH Q2(R1) GUIDELINES

Once a candidate chromatographic method has been optimised, it must be formally validated before it can be used for regulatory submission or routine quality control. The ICH Q2(R1) guideline, "Validation of Analytical Procedures: Text and Methodology," is the universally referenced framework for this purpose and is followed, explicitly or implicitly, by essentially all of the RP-HPLC methods reviewed in this article [9,10,15,17]. Table 3 summarises the key validation parameters required for an assay-type procedure of this kind, together with the acceptance criteria generally applied across the literature.